Levels of Circulating T Cells Expressing VLA-1 Collagen Receptors

This study has been completed.
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00708838
First received: July 1, 2008
Last updated: NA
Last verified: July 2008
History: No changes posted
  Purpose

The examination of the percentage of peripheral T cells carrying VLA-1 in ischemic heart disease patients. The hypothesis is that the percentage levels of cells carrying this integrin rise according to the severity of the ischemic heart disease.


Condition
Ischemic Heart Disease

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: VLA-1 Receptors on Peripheral T Cells in Ischemic Heart Disease Patients

Resource links provided by NLM:


Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • The differance in percentage of T cells in the 5 different groups involved. [ Time Frame: 2002-2006 ] [ Designated as safety issue: No ]

Biospecimen Retention:   None Retained

Blood samples isolated from patients included in the study and anallysed by FACS


Enrollment: 151
Study Start Date: January 2002
Study Completion Date: February 2007
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)

Detailed Description:

Atherosclerosis is considered an inflammatory disease in which lymphocytes have an important role. The study was disigned to find out the changes in T cell levels carrying VLA-1 involvement in this process.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Criteria

Inclusion Criteria:

  • clinical diagnosis of acute MI for group 1
  • clinical diagnosis of ACSl for group 2
  • clinical diagnosis of Chronic Heart Disease for groups 3 and 4
  • Chest pain but normal heart scan for group 5

Exclusion Criteria:

  • none
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Arik Asman, Sheba Medical Center, Heart Institute
ClinicalTrials.gov Identifier: NCT00708838     History of Changes
Other Study ID Numbers: SHEBA-02-2707-AA-CTIL
Study First Received: July 1, 2008
Last Updated: July 1, 2008
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Heart Diseases
Ischemia
Coronary Disease
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on July 23, 2014